CCL4 and Parkinson disease: Therefore, we conducted this MR analysis and reached a reliable result that one-SD increment in the circulating levels of MIP1b may increase the risk of PD by 6%, indicating that lowering the levels of MIP1b may be a promising therapeutic strategy for PD.